Navegar

Colección

Datos Estadísticas

Artículo

Lhommé, C.; Vermerken, J.B.; Mickiewicz, E.; Chevalier D', B.; Alvarez, A.; Mendiola, C.; Pawinski, A.; Lentz, M.A.; Pecorelli, S. "Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: An EORTC Gynaecological Cancer Cooperative Group Study" (2000) European Journal of Cancer. 36(2):194-199
Estamos trabajando para incorporar este artículo al repositorio
Consulte el artículo en la página del editor
Consulte la política de Acceso Abierto del editor

Abstract:

The objective of this phase II study was to assess the efficacy and toxicity of vinorelbine administered as a single agent in the treatment of chemonaive cervical cancer patients. 46 patients (41 eligible) with cervical cancer (epidermoid or adenocarcinoma) and measurable metastatic and/or recurrent disease localised outside irradiated areas were treated with weekly intravenous (i.v.) vinorelbine 30 mg/m2 infused over 20 min. No prior chemotherapy was allowed. Median age was 53 years (range: 33-73), and performance status 1 (0-2). 31 patients (76%) had prior radiation therapy. There were 7 partial responders (17, 95% confidence interval (CI) 7-32) and 8 stable diseases (20%). Median duration of response was 5 months (4-11). Granulocytopenia was the major toxicity, with 47% of patients exhibiting grade 3 or 4 toxicity. Dose reduction and/or treatment delay was necessary in 28 patients (78%). Peripheral neuropathy reported in 10 patients was mild (grade 1 in 9 patients and grade 2 in 1 patient). In conclusion, single agent vinorelbine has moderate activity in recurrent or metastatic cervical cancer, but its reduced neurotoxicity warrants further study in combination with cisplatin. (C) 2000 Elsevier Science Ltd.

Registro:

Documento: Artículo
Título:Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: An EORTC Gynaecological Cancer Cooperative Group Study
Autor:Lhommé, C.; Vermerken, J.B.; Mickiewicz, E.; Chevalier D', B.; Alvarez, A.; Mendiola, C.; Pawinski, A.; Lentz, M.A.; Pecorelli, S.
Filiación:Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
University Hospital Antwerpen, Wilrijkstraat, 2650 Edegem, Belgium
Instituto Angel H. Roffo, Universidad de Buenos Aires, Sucre 2741 8e, Buenos Aires 1428, Argentina
Centre H. Becquerel, Rue d'Amiens, 76038 Rouen Cedex, France
Hospital Universitario, 12 de Octubre, Ave. Cordoba Km 5,5, Madrid E-28041, Spain
EORTC and Memorial Cancer Center, Warsaw, Poland
EORTC, Ave E. Mounier 83 Bte 11, 1200 Brussels, Belgium
University of Brescia, Piazzale Spedale Civili, 2500 Brescia, Italy
Palabras clave:Cervical cancer; Chemotherapy; Phase II; Vinorelbine; navelbine; adult; advanced cancer; aged; article; cancer chemotherapy; cancer radiotherapy; clinical article; clinical trial; female; granulocytopenia; human; peripheral neuropathy; phase 2 clinical trial; priority journal; recurrent cancer; uterine cervix carcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Constipation; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Time Factors; Uterine Cervical Neoplasms; Vinblastine
Año:2000
Volumen:36
Número:2
Página de inicio:194
Página de fin:199
DOI: http://dx.doi.org/10.1016/S0959-8049(99)00237-3
Título revista:European Journal of Cancer
Título revista abreviado:Eur. J. Cancer
ISSN:09598049
CODEN:EJCAE
CAS:Antineoplastic Agents, Phytogenic; Vinblastine, 865-21-4; vinorelbine, 71486-22-1
Registro:https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_09598049_v36_n2_p194_Lhomme

Referencias:

  • Parkin, D.M., Laara, E., Muir, C.S., Estimates of the world wide frequency of sixteen major cancer in 1980 (1988) Int J Cancer, 41, pp. 184-197
  • Omura, G.A., Current status of chemotherapy for cancer of the cervix (1992) Oncology, 6, pp. 27-32
  • Vermorken, J.B., The rôle of chemotherapy in squamous cell carcinoma of the uterine cervix: A review (1993) Int J Gynecol Cancer, 3, pp. 129-142
  • Vermorken, J.B., Landoni, F., Pecorelli, S., Phase II study of vindesine in disseminated squamous cell carcinoma of the uterine cervix: An EORTC Gynecological cancer Cooperative Group study (1991) Int J Gynecol Cancer, 1, pp. 248-252
  • Rhomberg, W.U., Vindesine for recurrent and metastatic cancer of the uterine carvix: A phase II study (1986) Cancer Treat Rep, 70, pp. 1455-1457
  • Kavanagh, J.J., Copeland, L.J., Gershenson, D.M., Saul, P.B., Wharton, J.T., Rutledge, F.N., Continuous-infusion vinblastine in refractory carcinoma of the cervix: A phase II trial (1985) Gynecol Oncol, 21, pp. 211-214
  • Sutton, G.P., Blessing, J.A., Barnes, W., Ball, H., Phase II study of vinblastine in previously treated squamous carcinoma of the cervix. A Gynecologic Oncology Group study (1990) Am J Clin Oncol, 13, pp. 470-471
  • Langlois, N., Gueritte, F., Langlois, Y., Application of a modification of the Polonovski reaction to the synthesis of vinblastine-type alkaloid (1976) J Am Chem Soc, 22, pp. 7024-7071
  • Zavala, F., Guenad, D., Potier, P., Interaction of vinblastine analogues with tubulin (1978) Separatum Experiential, 34, p. 14971498
  • Fellous, A., Ohayon, R., Vacassin, T., Biochemical effects of Navelbine on tubulin and associated proteins (1989) Semin Oncol, 16 (4 SUPPL.), pp. 9-14
  • Johnson, S.A., Harper, P., Hortobagyi, G.N., Pouillart, P., Vinorelbine: An overview (1996) Cancer Treat Rev, 22, pp. 127-142
  • Khayat, D., Covelli, A., Variol, P., Benhamouda, A., Jacques, C., Bugat, R., Phase I and pharmacologie study of intravenous vinorelbine in patients with solid tumours (1995) Proc Am Soc Clin Oncol, 14, pp. A1518
  • (1979) WHO Handbook for Reporting Results of Cancer Treatment, , WHO offset publication no. 28. Geneva, Switzerland, World Health Organisation
  • Gehan, E.A., The determination of the number of patients required in a follow-up trial of a new chemotherapeutic agent (1961) J Chron Dis, 13, pp. 346-353
  • Kaplan, E., Meier, F., Nonparametric estimation from incomplete observations (1958) J Am Stat Assoc, 58, pp. 457-481
  • Omura, G.A., Chemotherapy for stage IVB or recurrent cancer of the uterine cervix (1996) J Natl Cancer Inst Monogr, 21, pp. 123-126
  • Vermorken, J.B., Zanetta, G., De Oliviera, C.F., Cisplatin-based combination chemotherapy (BEMP) versus single agent cisplatin (P) in disseminated squamous-cell carcinoma of the uterine cervix (SCUCC): Mature data EORTC protocol 55863 (1996) Ann Oncol, 7 (5 SUPPL.), p. 67. , abstract 318
  • Vermorken, J.B., (1996) Palliative Chemotherapy for Patients with Cervical Cancer. What Is Standard?, p. 6367. , ESMO Educational Book
  • Bonomi, Ph., Blessing, J.A., Stehman, F.B., DiSaia, P.J., Walton, N., Major, F.J., Randomized trial of three cisplatin dose schedule in squamous-cell carcinoma of the cervix: A Gynecologic Oncology Group study (1985) J Clin Oncol, 3, pp. 1079-1085
  • Hreshchyshyn, M., Vincristine treatment of patients with carcinoma of the uterine cervix (1963) Proc AACR, 4, p. 29
  • Holland, J.F., Scharlau, C., Gailani, S., Vincristine treatment of advanced cancer: A cooperative study of 392 cases (1973) Cancer Res, 33, pp. 1258-1264
  • Jackson, D.V., Jobson, V.W., Homesley, H.D., Vincristine infusion in refractory gynecologic malignancies (1986) Gynecol Oncol, 25, pp. 212-216
  • Kavanagh, J.J., Copeland, L., Gershenson, D., Roberts, W., Continous infusion vinblastine for treatment and refractory adenocarcinoma of the cervix (1987) Cancer Treat Rep, 71, pp. 547-548
  • Morris, M., Brader, K.R., Levenback C.s, Phase II study of vinorelbine in advanced and (1998) J Clin Oncol, 16, pp. 1094-1098
  • Lacava, J.A., Leone, B.A., Machiavelli, M., Vinorelbine as neoadjuvant chemotherapy in advanced cervical carcinoma (1997) J Clin Oncol, 15, pp. 604-609

Citas:

---------- APA ----------
Lhommé, C., Vermerken, J.B., Mickiewicz, E., Chevalier D', B., Alvarez, A., Mendiola, C., Pawinski, A.,..., Pecorelli, S. (2000) . Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: An EORTC Gynaecological Cancer Cooperative Group Study. European Journal of Cancer, 36(2), 194-199.
http://dx.doi.org/10.1016/S0959-8049(99)00237-3
---------- CHICAGO ----------
Lhommé, C., Vermerken, J.B., Mickiewicz, E., Chevalier D', B., Alvarez, A., Mendiola, C., et al. "Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: An EORTC Gynaecological Cancer Cooperative Group Study" . European Journal of Cancer 36, no. 2 (2000) : 194-199.
http://dx.doi.org/10.1016/S0959-8049(99)00237-3
---------- MLA ----------
Lhommé, C., Vermerken, J.B., Mickiewicz, E., Chevalier D', B., Alvarez, A., Mendiola, C., et al. "Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: An EORTC Gynaecological Cancer Cooperative Group Study" . European Journal of Cancer, vol. 36, no. 2, 2000, pp. 194-199.
http://dx.doi.org/10.1016/S0959-8049(99)00237-3
---------- VANCOUVER ----------
Lhommé, C., Vermerken, J.B., Mickiewicz, E., Chevalier D', B., Alvarez, A., Mendiola, C., et al. Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: An EORTC Gynaecological Cancer Cooperative Group Study. Eur. J. Cancer. 2000;36(2):194-199.
http://dx.doi.org/10.1016/S0959-8049(99)00237-3